MX2022012181A - Metodos y composiciones para tratar cancer. - Google Patents

Metodos y composiciones para tratar cancer.

Info

Publication number
MX2022012181A
MX2022012181A MX2022012181A MX2022012181A MX2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating cancer
ppp2r2a
pkmyt1
Prior art date
Application number
MX2022012181A
Other languages
English (en)
Inventor
Stephen Harrison
Christine Taylor Brew
Michael David Winther
Sourabh Banerjee
Shawn Yost
Original Assignee
Engine Biosciences Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engine Biosciences Pte Ltd filed Critical Engine Biosciences Pte Ltd
Publication of MX2022012181A publication Critical patent/MX2022012181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se describen métodos y composiciones para tratar cáncer. Los métodos pueden comprender el uso de cantidades terapéuticamente efectivas de uno o más agentes para provocar una diferencia en la expresión o actividad de la proteína cinasa, tirosina/treonina 1 asociada a membrana (PKMYT1) en células de cáncer que son deficientes en la subunidad B alfa reguladora de proteína fosfatasa 2 (PPP2R2A).
MX2022012181A 2020-04-01 2021-03-31 Metodos y composiciones para tratar cancer. MX2022012181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003736P 2020-04-01 2020-04-01
PCT/US2021/025230 WO2021202780A2 (en) 2020-04-01 2021-03-31 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2022012181A true MX2022012181A (es) 2023-01-30

Family

ID=77927411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012181A MX2022012181A (es) 2020-04-01 2021-03-31 Metodos y composiciones para tratar cancer.

Country Status (9)

Country Link
US (1) US20230149415A1 (es)
EP (1) EP4127722A4 (es)
JP (1) JP2023519931A (es)
KR (1) KR20230017167A (es)
CN (1) CN115769077A (es)
AU (1) AU2021249111A1 (es)
CA (1) CA3173799A1 (es)
MX (1) MX2022012181A (es)
WO (1) WO2021202780A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398799A1 (en) * 2021-08-19 2024-12-05 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
KR20250136774A (ko) * 2024-03-08 2025-09-16 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2025215187A1 (en) 2024-04-11 2025-10-16 My-T Bio Limited Therapeutic compounds and their use
WO2025215188A1 (en) 2024-04-11 2025-10-16 My-T Bio Limited Therapeutic compounds and their use as inhibitors of pkmyt1
WO2025242880A1 (en) 2024-05-24 2025-11-27 My-T Bio Limited Therapeutic compounds and their use
WO2026057597A1 (en) 2024-09-10 2026-03-19 My-T Bio Limited Pkmyt1 inhibitors and their use
WO2026057598A1 (en) 2024-09-10 2026-03-19 My-T Bio Limited Therapeutic compounds as pkmyt1 inhibitors and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
EP3313819A1 (en) * 2015-06-23 2018-05-02 Case Western Reserve University Compositions and methods for treating cancer

Also Published As

Publication number Publication date
WO2021202780A2 (en) 2021-10-07
EP4127722A4 (en) 2024-05-01
JP2023519931A (ja) 2023-05-15
US20230149415A1 (en) 2023-05-18
WO2021202780A3 (en) 2021-11-11
CN115769077A (zh) 2023-03-07
AU2021249111A1 (en) 2022-10-20
CA3173799A1 (en) 2021-10-07
EP4127722A2 (en) 2023-02-08
KR20230017167A (ko) 2023-02-03

Similar Documents

Publication Publication Date Title
MX2022012181A (es) Metodos y composiciones para tratar cancer.
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12020551180A1 (en) Methods and compositions for therapeutic protein delivery
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
ZA202204284B (en) Inhibitors of raf kinases
MX2021001884A (es) Compuestos de pirazina y usos de los mismos.
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
BR112016008016B8 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
SG10201902664RA (en) Combination therapy for treating cancer
MX2020009773A (es) Terapia de combinacion.
MX420412B (es) Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2022003570A (es) Composiciones de vesícula extracelular.
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
PH12022551468A1 (en) Compounds active towards nuclear receptors
JOP20230250A1 (ar) تركيبات وطرق لتثبيط إنزيم كيتوهيكسوكيناز (khk)
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of